DELCATH SYSTEMS INC (DCTH)
US24661P8077 - Common Stock
Top Buys by Directors: Salamon's $100K Bet on DCTH
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...
DCTH Stock Earnings: Delcath Systems Beats EPS, Misses Revenue for Q4 2023
DCTH stock results show that Delcath Systems beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
DCTH Stock Earnings: Delcath Systems Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Delcath Systems (NASDAQ:DCTH) just reported results for the fourth quarter of 2...
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and...
Friday 3/22 Insider Buying Report: DCTH, ARWR
Delcath Systems Closes $7 Million Private Placement
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...
Delcath Systems Announces $7 Million Private Placement
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...
Delcath Systems to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...
Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath launches Hepzato Kit in US for uveal melanoma (NASDAQ:DCTH)
Delcath Systems (DCTH) has launched Hepzato Kit in the US, a treatment for metastatic uveal melanoma. Read more here.
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...
Delcath Systems CEO discloses purchase of 34K shares (NASDAQ:DCTH)
Delcath Systems CEO purchases 34K shares worth $99,960, leading to an 8% increase in DCTH stock.
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and...
Wednesday 10/18 Insider Buying Report: BYRN, DCTH
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...